- Home
- ATAI vs IMAB Comparison
ATAI vs IMAB Comparison
Compare ATAI & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATAI
- IMAB
- Stock Information
- Founded
- ATAI 2018
- IMAB 2014
- Country
- ATAI Germany
- IMAB United States
- Employees
- ATAI N/A
- IMAB N/A
- Industry
- ATAI Biotechnology: Pharmaceutical Preparations
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- ATAI Health Care
- IMAB Health Care
- Exchange
- ATAI Nasdaq
- IMAB Nasdaq
- Market Cap
- ATAI 444.7M
- IMAB 384.6M
- IPO Year
- ATAI 2021
- IMAB 2020
- Fundamental
- Price
- ATAI $4.72
- IMAB $3.65
- Analyst Decision
- ATAI Strong Buy
- IMAB Strong Buy
- Analyst Count
- ATAI 3
- IMAB 5
- Target Price
- ATAI $13.33
- IMAB $6.80
- AVG Volume (30 Days)
- ATAI 4.8M
- IMAB 1.7M
- Earning Date
- ATAI 11-12-2025
- IMAB 11-02-2025
- Dividend Yield
- ATAI N/A
- IMAB N/A
- EPS Growth
- ATAI N/A
- IMAB N/A
- EPS
- ATAI N/A
- IMAB N/A
- Revenue
- ATAI $2,309,000.00
- IMAB N/A
- Revenue This Year
- ATAI $712.99
- IMAB N/A
- Revenue Next Year
- ATAI N/A
- IMAB N/A
- P/E Ratio
- ATAI N/A
- IMAB N/A
- Revenue Growth
- ATAI 510.85
- IMAB N/A
- 52 Week Low
- ATAI $1.03
- IMAB $0.60
- 52 Week High
- ATAI $5.34
- IMAB $5.90
- Technical
- Relative Strength Index (RSI)
- ATAI 61.12
- IMAB 44.80
- Support Level
- ATAI $4.50
- IMAB $3.20
- Resistance Level
- ATAI $4.75
- IMAB $4.64
- Average True Range (ATR)
- ATAI 0.28
- IMAB 0.38
- MACD
- ATAI -0.04
- IMAB -0.16
- Stochastic Oscillator
- ATAI 59.28
- IMAB 30.20
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).